Shots:
Orion Pharma & Qilu Pharma EU have entered into an agreement to commercialise IV pembrolizumab biosimilar in Europe, which is currently developed by Qilu
As per the deal, Orion will gain exclusive right to distribute, market & sell Qilu’s IV pembrolizumab biosimilar in the EU, while Qilu will supply the product & receive a…
